

Developing Regenerative Gene Therapies with the Potential to Transform Respiratory Medicine
Game Changing Innovation in Respiratory Medicine
At OmniSpirant, we believe our technology has the potential to positively impact the lives of millions of patients. We have created a bold new approach to treat currently incurable respiratory diseases that affect hundreds of millions of people worldwide. Our planned pipeline of advanced therapies intersect regenerative medicine and gene therapy in the hope of treating these devastating lung diseases of severely unmet patient need. Our patent pending platform technology is based on inhaled bioengineered stem cell exosomes which are capable of efficient intracellular delivery of a variety of therapeutic cargoes to effectively treat these diseases at the required level of complexity. Our engineered stem cell exosomes will initially be used to develop a first in class regenerative gene therapy for Cystic Fibrosis. The prorietatry mucus penetrating exosomes have similar transformative potential for treating many other respiratory diseases. Please browse our site to learn more about our mission and technology.


INHALED EXOSOME TECHNOLOGY PLATFORM
Exosomes genetic cargo can be tailored to treat virtually any lung disease

Exosomes exhibit unparalleled intracellular delivery and therapeutic properties

